Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guangdong South China Pharmaceutical Group BCL-2 inhibitor
- Development stage
- Preclinical
- Lead developer
- Ascentage Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Guangdong South China Pharmaceutical Group BCL-2 inhibitor is a preclinical small molecule therapeutic being developed for the treatment of hematologic malignancies. This asset is the result of a collaboration between the Guangdong South China Pharmaceutical Group (also known as the South China Center for Innovative Pharmaceuticals) and the Shanghai Institute of Materia Medica (SIMM). The drug's mechanism of action involves the selective inhibition of B-cell lymphoma 2 (BCL-2), an anti-apoptotic protein that is frequently overexpressed in various blood cancers, allowing malignant cells to evade programmed cell death. By antagonizing BCL-2, the compound aims to restore the natural apoptotic pathway, leading to the death of tumor cells. It is currently in the preclinical stage of development.
- Other names
- BCL-2 inhibitorBCL2 inhibitorBCL 2 inhibitorBCL-2 small molecule inhibitorBCL2 small molecule inhibitorBCL 2 small molecule inhibitor
02
Targets
BCL2L1 (B-cell lymphoma-extra large protein)
Beyond the preview
Go deeper on Guangdong South China Pharmaceutical Group BCL-2 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guangdong South China Pharmaceutical Group BCL-2 inhibitor.